New filler takes on restylane for wrinkle correction
NCT ID NCT07150273
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested a new dermal filler called UNIVELO Sub-Q against the well-known Restylane Sub-Q for temporarily smoothing deep smile lines (nasolabial folds). 65 adults with moderate to severe wrinkles received both fillers on opposite sides of their face. Researchers measured wrinkle severity and aesthetic improvement over 48 weeks to see if the new filler works as well as the existing one.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- UNIVELO Sub-Q (dermal filler injection)
- What this could lead to
- If it works, this could offer a new option for temporarily reducing deep smile lines, similar to existing fillers.
- What could go wrong
- This is a small, single-center study comparing two fillers. Results may not apply to everyone, and effects are temporary. Risks include swelling, bruising, or uneven results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
65 people
The number who actually took part.
- Started
-
Feb 2016
- Finished
-
Jul 2017
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects who desire temporary improvement of both nasolabial folds and who has rated 3 or 4 on the Wrinkle Severity Rating Scale (WSRS) (the rating does not have to be the same for both sides) * Subjects who have agreed to discontinue all dermatological treatments or procedures, including those for facial wrinkles improvement in the facial area, during the clinical trial period * Subjects capable of understanding and complying with directions and who can participation for the full duration of the clinical trial period * Subjects who have voluntarily decided to participate in the clinical trial and have given written consent by signing the subject informed consent form Exclusion Criteria: * Subjects who have been administered an antithrombotic agent (with the exception of low dosage aspirin (100mg, maximum 300mg/day)) within 2 weeks of the date of the screening * Subjects who have had a history of any bleeding disorder, in the past or the present
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nasolabial fold are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.